Samsung Biologics Signs Pharmaceutical Contract Manufacturing Agreement Worth 112.1 Billion KRW
[Asia Economy Reporter Lee Gwan-ju] Samsung Biologics announced on the 28th that it has signed a contract for contract manufacturing organization (CMO) with the global pharmaceutical company 'Eli Lilly Kinsale Limited.' The contract amount is approximately 112.13391 billion KRW.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The company stated, "The contract was initially signed on December 20, 2019, and the confirmed sales amount has increased due to the customer's increased demand," adding, "The confirmed contract amount may increase to 177.45 million USD through further negotiations with the customer."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
